Sosman Joins the Lurie Cancer Center Named Co-Leader, Translational Research in Solid Tumors Program
Jeffrey Sosman, MD, a highly esteemed oncologist and internationally recognized melanoma expert and researcher, will join the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as Co-Leader of the Translational Research in Solid Tumors (TRIST) Program and Director of the Melanoma Program. He will also serve as Director for Faculty Development at the Lurie Cancer Center. Sosman has been appointed professor of Medicine at the Feinberg School of Medicine.
Sosman will join the Lurie Cancer Center on May 1 from Vanderbilt-Ingram Cancer Center where he has an Ingram Chair for Cancer Research and directs the Melanoma Program and is Co-Leader of the Translational Research and Interventional Oncology Program. He also received the first Mary Hendrickson-Johnson American Cancer Society Melanoma Research Professorship in 2009, which he continues to hold through 2018.
The overall goal of the TRIST Program is to coordinate and enhance the interactions among researchers in the area of solid cancers at Northwestern University. The program consists of accomplished faculty conducting translational studies centered on the themes of molecular and cell biology, early diagnosis, prognosis, risk factors, therapeutics and treatment of cancer of the aerodigestive tract, dermatologic, gastrointestinal, genitourinary and neuro-oncologic cancers. Dr. Sosman’s expertise makes him ideal to co-lead such a program.
“We are excited that Dr. Sosman will be joining us,” said Leonidas Platanias, MD, PhD, Director of the Lurie Cancer Center. “He is among the country’s top researchers in cancer immunotherapy and melanoma clinical trials. His experience and superb clinical research work will substantially strengthen our ability to bring novel new treatments to our patients.”
Dr. Sosman is widely recognized for his initiatives to bring translational medicine to melanoma therapy. His research includes the study of this most deadly form of skin cancer that has seen great breakthroughs in both targeted therapy and immune-based therapy in recent years.
Dr. Sosman has been a key contributor to many of the seminal trials which led to approval of at least eight new therapeutic agents for melanoma in the past five years. He continues to study new investigational agents to further increase treatment options for patients with melanoma. He is also widely recognized for his work with malignancies other than melanoma, such as renal cell carcinoma.
The trials conducted by Sosman frequently include a strong translational component centered on immunotherapy, or on targeted therapy aimed at mutated or overexpressed oncogenes. He has been the lead author or co-author on numerous high-impact papers on melanoma, and was named one of the “Hottest Scientific Researchers” in 2013 by Thomson Reuters ScienceWatch.